[0007b] In another aspect of the present disclosure, there is provided a use of a compound represented by:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a tenosynovial giant cell tumor in a patient in need thereof, wherein 2 mg to 50 mg of the compound is to be orally administered to the patient twice weekly.

[0007c] In a further aspect of the present disclosure, there is provided Use of a compound represented by:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a tenosynovial giant cell tumor in a patient in need thereof, wherein 30 mg of the compound is to be orally administered to the patient twice weekly.

[0008] The disclosure also provides for a method of treating tumors, e.g., GCTTS, PVNS, TGCT or DTGCT, comprising administering to the patient a therapeutically effective amount of the compound 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one or a pharmaceutically acceptable salt thereof, wherein administering comprises: administering a loading dose of the compound daily for a first time period; and administering a maintenance dose of the compound once a week, twice a week, or three times a week for a second time period.

[0009] A method of inhibiting the proliferation of a cell known to have expression of the receptor colony-stimulating factor 1 receptor (CSF1R) or its ligands, colony-stimulating factor 1 (CSF1) or interleukin (IL)-34 in a patient in need thereof is also contemplated herein,